[Form 4] UTAH MEDICAL PRODUCTS INC Insider Trading Activity

Rhea-AI Filing Summary

Utah Medical Products Inc. (UTMD) reported an equity compensation award to its Principal Financial Officer. On 10/31/2025, the officer received an employee stock option to buy 500 shares of UTMD common stock at an exercise price of $58.1 per share. The option expires on 10/31/2035 and will vest 25% on 1/1/27, with an additional 6.25% vesting on 4/1/27 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 1/1/30. Following this grant, the officer beneficially owned 5,600 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koopman Brian

(Last) (First) (Middle)

108 E 1700 S

(Street)

BOUNTIFUL UT 84010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UTAH MEDICAL PRODUCTS INC [ UTMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option - Right to Buy	$58.1	10/31/2025		A		500		01/01/2030(1)	10/31/2035	Common Stock	500	$0	5,600	D

Explanation of Responses:

1. Option will vest 25% on 1/1/27, and an additional 6.25% on 4/1/27 and the first day of each calendary quarter thereafter. Fully exercisable on 1/1/30.

	/s/ Brian L. Koopman	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UTMD report in this Form 4 filing?

Utah Medical Products Inc. reported that its Principal Financial Officer received an employee stock option on 10/31/2025 to buy 500 shares of UTMD common stock at an exercise price of $58.1 per share.

What is the exercise price and size of the UTMD stock option grant?

The employee stock option covers 500 shares of UTMD common stock with an exercise price of $58.1 per share.

When do the UTMD options granted on 10/31/2025 vest and become fully exercisable?

The option vests 25% on 1/1/27, then 6.25% on 4/1/27 and on the first day of each calendar quarter thereafter, and is fully exercisable on 1/1/30.

When do the UTMD employee stock options granted to the officer expire?

The employee stock option granted on 10/31/2025 expires on 10/31/2035.

How many derivative securities does the UTMD officer own after this transaction?

After the reported transaction, the officer beneficially owned 5,600 derivative securities, held directly.

What is the relationship of the reporting person to Utah Medical Products Inc. (UTMD)?

The reporting person is an officer of Utah Medical Products Inc., serving as Principal Financial Officer.